Primary Site >> Biliary tract Cancer
Gene >> ERBB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. PMID: 1374219 |
Ref: Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. PMID: 8683379 Ref: Hereditary onset of multiple seborrheic keratoses: a variant of Leser Trelat sign? PMID: 8935630 |
Ref: NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. PMID: 9403719 |
Ref: Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. PMID: 9537436 |
Ref: Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. PMID: 10216129 |
Ref: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. PMID: 11261824 Ref: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. PMID: 11357901 Ref: Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. PMID: 11677943 |
Ref: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. PMID: 11895493 Ref: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. PMID: 12044528 |
Ref: Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. PMID: 12846405 |
Ref: MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. PMID: 14752841 Ref: Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. PMID: 15010878 Ref: Establishment and characterization of unique human gallbladder cancer cell lines. PMID: 15067341 Ref: Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. PMID: 15209630 |
Ref: Characterization and genetic analysis in the newly established human bile duct cancer cell lines. PMID: 15645130 Ref: [Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma]. PMID: 15665568 Ref: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. PMID: 15921858 Ref: Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. PMID: 16061875 Ref: FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. PMID: 16311342 Ref: erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. PMID: 16344070 Ref: Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. PMID: 19956499 |
Ref: Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. PMID: 16686942 Ref: MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. PMID: 16857800 |
Ref: Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. PMID: 17322545 Ref: Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. PMID: 17440093 Ref: Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. PMID: 17595796 Ref: Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. PMID: 17690040 Ref: [Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]. PMID: 18159174 Ref: HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. PMID: 19262900 |
Ref: A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. PMID: 18081149 Ref: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. PMID: 18087285 Ref: MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. PMID: 18397823 Ref: EGFR expression in gallbladder carcinoma in North America. PMID: 18825277 Ref: Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. PMID: 18936968 Ref: Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. PMID: 19084911 |
Ref: A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. PMID: 19262069 Ref: Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. PMID: 19331129 Ref: Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma. PMID: 19621664 Ref: EGFR and HER2 expression in advanced biliary tract cancer. PMID: 19777609 Ref: CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. PMID: 20007080 |
Ref: Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening. PMID: 19780758 Ref: Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. PMID: 20040392 Ref: Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. PMID: 20607690 Ref: Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu. PMID: 20655306 Ref: High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. PMID: 20731018 Ref: Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. PMID: 20816680 |
Ref: Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. PMID: 21492330 |
Ref: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. PMID: 22178589 Ref: The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. PMID: 22326466 Ref: Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. PMID: 22468084 Ref: Role of C-erbB2 expression in gallbladder cancer. PMID: 22499306 Ref: HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. PMID: 23052372 |
Ref: Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. PMID: 23391555 Ref: Expression of procaspase 3 and activated caspase 3 and its relevance in hormone-responsive gallbladder carcinoma chemotherapy. PMID: 24009453 |
Ref: Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. PMID: 23828315 Ref: Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. PMID: 24255171 Ref: Molecular aspects of cholangiocarcinoma. PMID: 24420749 Ref: Genomic and transcriptional alterations of cholangiocarcinoma. PMID: 24532422 Ref: Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. PMID: 24787096 Ref: Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. PMID: 24799970 Ref: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. PMID: 24837095 Ref: A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done. PMID: 24857099 Ref: Characterization of EGFR family gene aberrations in cholangiocarcinoma. PMID: 24927194 Ref: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. PMID: 24997986 Ref: Interaction of Muc4 and ErbB2 in a transgenic mouse model of gallbladder carcinoma: potential pathobiological implications. PMID: 25174601 Ref: SOX4 is associated with poor prognosis in cholangiocarcinoma. PMID: 25181339 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer. PMID: 24839254 Ref: Prognostic value of increased HER2 expression in cancers of pancreas and biliary tree. PMID: 25416598 Ref: Microsatellite instability in gallbladder carcinoma. PMID: 25680569 Ref: HER2 expression status in diverse cancers: review of results from 37,992 patients. PMID: 25712293 Ref: Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia. PMID: 25770659 Ref: Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). PMID: 25975284 Ref: HER2/neu-directed therapy for biliary tract cancer. PMID: 26022204 Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. PMID: 26111977 Ref: Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PMID: 26571380 |
Ref: Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. PMID: 26486326 Ref: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. PMID: 26500333 Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. PMID: 26758058 Ref: Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. PMID: 26857926 Ref: EGFR and HER-2/neu Expression in Gallbladder Carcinoma: An Institutional Experience. PMID: 27050174 Ref: [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. PMID: 27171333 Ref: Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. PMID: 27267833 Ref: Therapeutic implication of HER2 in advanced biliary tract cancer. PMID: 27517322 Ref: Biliary cancer: Utility of next-generation sequencing for clinical management. PMID: 27622582 Ref: Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma. PMID: 27644637 Ref: Molecular profiling of biliary tract cancer: a target rich disease. PMID: 27747093 |
Ref: HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? PMID: 27981460 Ref: Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. PMID: 28223426 Ref: The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. PMID: 28285962 Ref: [Clinical significance of HER2 positivity in gallbladder adenocarcinoma]. PMID: 28376590 Ref: High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. PMID: 28467612 Ref: The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. PMID: 28567120 Ref: Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. PMID: 28671339 Ref: Current biologics for treatment of biliary tract cancers. PMID: 28736630 Ref: Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma. PMID: 28843919 |
Ref: Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. PMID: 29416916 Ref: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. PMID: 29460642 Ref: MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. PMID: 29731265 Ref: Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. PMID: 29848569 Ref: New developments in systemic therapy for advanced biliary tract cancer. PMID: 29893894 Ref: Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. PMID: 29914418 Ref: Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. PMID: 29954840 Ref: Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder. PMID: 30155833 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PMID: 30335866 |